Chuanjuan Tao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11746492/publications.pdf

Version: 2024-02-01

10	869	1040056 9	1372567 10
papers	citations	h-index	g-index

14	14	14	1327
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. Journal of Proteome Research, 2020, 19, 4690-4697.	3.7	223
2	Real-time single-molecule electronic DNA sequencing by synthesis using polymer-tagged nucleotides on a nanopore array. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5233-5238.	7.1	114
3	PEG-Labeled Nucleotides and Nanopore Detection for Single Molecule DNASequencing by Synthesis. Scientific Reports, 2012, 2, 684.	3.3	109
4	A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral Research, 2020, 180, 104857.	4.1	100
5	Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. Scientific Reports, 2020, 10, 16577.	3.3	65
6	In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. Journal of Antimicrobial Chemotherapy, 2021, 76, 1874-1885.	3.0	65
7	Nucleotide analogues as inhibitors of SARSâ€CoV Polymerase. Pharmacology Research and Perspectives, 2020, 8, e00674.	2.4	56
8	Design and characterization of a nanopore-coupled polymerase for single-molecule DNA sequencing by synthesis on an electrode array. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6749-E6756.	7.1	46
9	Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. Communications Biology, 2022, 5, 154.	4.4	40
10	Identifying Structural Features of Nucleotide Analogues to Overcome SARS-CoV-2 Exonuclease Activity. Viruses, 2022, 14, 1413.	3.3	6